News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

FASN inhibitor for MASH with fibrosis gets a pass to phase III
28 Oct 2024
byJairia Dela Cruz
The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.
28 Oct 2024

Survodutide safe to use in cirrhosis patients
27 Oct 2024
Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.
27 Oct 2024

Semaglutide helps prevent HF events, CV death in diabetic patients with CKD
24 Oct 2024
byStephen Padilla
Treatment with semaglutide can significantly lower the risk of time to first heart failure (HF) events or cardiovascular (CV) death in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), a recent study has shown.
24 Oct 2024





